Medicare tightens rules after alleged $3 billion fraud scheme; new Alzheimer disease diagnostic criteria are causing controversy; loss of Medicaid is tied to struggles affording health care.
A $3 billion suspected scam involving urinary catheters has exposed vulnerabilities in Medicare and prompted calls for reform, according to the Washington Post. For over a year, a dozen companies allegedly submitted fraudulent bills for tens of millions of catheters using patient and doctor information. Experts say this isn't a new problem. Medicare is a prime target for fraud, and combating claims for unnecessary durable medical equipment has been a longstanding challenge. Health care providers and lawmakers are urging the government to crack down on the companies and improve antifraud efforts. The National Association of Accountable Care Organizations (ACOs), which advocated for a policy remedy to the catheter billing issues, issued a statement that it “applauds CMS for implementing stakeholder recommendations to hold ACOs harmless for significant anomalous and highly suspect catheter expenditures in 2023.”
Amid the approval of donanemab for early Alzheimer disease, the Alzheimer Association has published new criteria for doctors diagnosing the disease, according to CNN. The criteria suggest that rather than relying on memory and thinking tests, doctors should diagnose the disease based on biomarkers: pieces of β-amyloid and tau proteins picked up by lab tests or on brain scans. However, some experts have argued that some people can have β-amyloid proteins in their brains and blood without ever developing dementia symptoms. There is concern within the medical field that the new diagnosis criteria will expand the number of people eligible for the new Alzheimer disease drugs, generating huge profit margins for manufacturers. The Alzheimer Association clarified that the new criteria should serve as a bridge between research and doctor diagnosis.
A study on low-income adults in 4 southern US states found that losing Medicaid coverage after COVID-19 protections ended led to struggles affording health care and prescription drugs for many, according to CIDRAP. Nearly half of those disenrolled from Medicaid were uninsured in late 2023. This could widen a gap that had narrowed during the time when governmental benefits were expanded; for instance, adults with low incomes were less likely to delay or forgo health care due to cost during the pandemic vs before.
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
High Drug Costs, PBM Reform, and Access Challenges Take Center Stage at AMCP 2025
March 25th 2025As managed care pharmacy navigates rapid transformations in policies, high-cost drug strategies, and innovative therapies, the upcoming AMCP annual meeting will provide critical insights into legislative impacts, drug affordability, formulary design, and emerging treatment trends.
Read More